Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GHRP-1 - QLT USA

Next Previous
Drug Profile

GHRP-1 - QLT USA

Alternative Names: Growth hormone releasing peptide-1 - Atrix Laboratories

Latest Information Update: 24 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tulane University
  • Developer QLT USA
  • Class Oligopeptides
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cachexia; Nutrition disorders; Short stature

Most Recent Events

  • 01 Oct 2009 QLT USA has been acquired by Tolmar
  • 22 Nov 2004 Atrix Laboratories has been acquired by QLT
  • 24 Jun 2004 Phase-I clinical trials in Cachexia in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top